×
More Charts Below
Pulmonx Total Non-Operating Income/Expense 2019-2024 | LUNG
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Recent Trends
Pulmonx total non-operating income/expense from 2019 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Veeva Systems (VEEV)
$35.1B
Tempus AI (TEM)
$7B
Hims & Hers Health (HIMS)
$6B
Inspire Medical Systems (INSP)
$4.5B
IRhythm Technologies (IRTC)
$3.2B
Privia Health (PRVA)
$2.9B
Schrodinger (SDGR)
$1.9B
Clover Health Investments (CLOV)
$1.8B
Enovis (ENOV)
$1.8B
Omnicell (OMCL)
$1.4B
Phreesia (PHR)
$1.4B
Azenta (AZTA)
$1.2B
10x Genomics (TXG)
$918M
Butterfly Network (BFLY)
$568M
Fulgent Genetics (FLGT)
$551M
Talkspace (TALK)
$450M
Veradigm (MDRX)
$449M
Standard BioTools (LAB)
$440M
TruBridge (TBRG)
$363M
Claritev (CTEV)
$325M
Health Catalyst (HCAT)
$270M
Nyxoah SA (NYXH)
$206M
SOPHiA GENETICS SA (SOPH)
$189M
American Well (AMWL)
$109M
EUDA Health Holdings (EUDA)
$100M
Retrieve Medical Holdings (RMHI)
$82M
MDxHealth SA (MDXH)
$76M
P3 Health Partners (PIII)
$66M
111 (YI)
$64M
CareCloud (CCLD)
$60M